Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Ate'$ next mission

<< Previous

Bullboard Posts

Next >>

Comment by Amigo11on Jul 20, 2021 6:31am

236 Views

Post# 33574034

RE:Ate'$ next mission

With about $1.85 in cash per share ,investors are really paying $1.40 per share for all the upside of ATE.As we didn't have any cash per share for most of our existence,a prospective investor hasnt paid this little for all the upsidd in a long time.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features